Article
Integrating AI-MIDD with Mechanistic Erythropoietin Modeling: A Digital-Twin Framework for Optimizing ESA Therapies
2025-11-13
Abstract excerpt
Erythropoiesis-stimulating agents (ESAs) remain a mainstay for anemia therapy, yet variability in response and emerging resistance mechanisms limit their effectiveness. We developed a hybrid AI-MIDD (Model-Informed Drug Development) and Quantitative Systems Pharmacology (QSP) platform and applied it for integrating mechanistic signaling (EPO–EpoR–JAK2/STAT5–SOCS3/CIS) with metabolic (mTOR), iron-homeostatic (hepci...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e6b3ae10-2f14-5468-8ad1-ca39d6cbdd3d
- DOI
- 10.1101/2025.11.12.688044
